Reese AB. Persistent hyperplastic primary vitreous. Am J Ophthalmol, 1955, 40(3): 317-331.
[2]
Son AI, Sheleg M, Cooper MA, et al. Formation of persistent hyperplastic primary vitreous in ephrin-A5-/- mice. Invest Ophthalmol Vis Sci, 2014, 55(3): 1594-1606. DOI: 10.1167/ iovs.13-12706.
[3]
Grenga R, Komaiha C, Bianchi G, et a1.Persistent hyperplastic primary vitreous: Case report and literature review. Clin Ter, 2013, 164(6): e497-503. DOI: 10.7417/CT.2013.1644.
[4]
Haddad R, Font RL, Reeser F. Persistent hyperplastic primary vitreous. A clinicopathologic study of 62 cases and review of the literature. Surv Ophthalmol, 1978, 23(2): 123-134.
[5]
Goldberg MF. Persistent fetal vasculature (PFV): An integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. Am J Ophthalmol, 1997, 124(5): 587-626.
[6]
Pollard ZF. Persistent hyperplastic primary vitreous: diagnosis, treatment and results. Trans Am Ophthalmol Soc, 1997, 95: 487- 549.
Bata BM, Chiu HH, Mireskandari K, et al. Long-term visual and anatomic outcomes following early surgery for persistent fetal vasculature: A single-center, 20-year review. J AAPOS, 2019, 23(6): 327.e1-327.e5. DOI: 10.1016/j.jaapos.2019.07.009.
[10]
Sisk RA, Berrocal AM, Feuer WJ, et al. Visual and anatomic outcomes with or without surgery in persistent fetal vasculature. Ophthalmology, 2010, 117(11): 2178-2183.e1-2. DOI: 10.1016/ j.ophtha.2010.03.062.
[11]
Hunt A, Rowe N, Lam A, et al. Outcomes in persistent hyperplastic primary vitreous. Br J Ophthalmol, 2005, 89(7): 859-863. DOI: 10.1136/bjo.2004.053595.